Prospective, Randomized, Controlled, Multicentre, Open Study Releas of Paclitaxel during PTA versus PTA alone for the treatment of de-novo occluded, stenotic or reoccluded, restenotic superficial femoral (SFA) or popliteal arteries.
Phase 4
Withdrawn
- Conditions
- narrowing of the bloodvesselstenosis10003216
- Registration Number
- NL-OMON35958
- Lead Sponsor
- Eurocor GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
Patients with symptomatic ischemia, requiring treatment of SFA or popliteal artery
Exclusion Criteria
Pregnancy, aneurisma disease of the abdominal aorta, iliac or popliteal arteries, contraindication for anti platelet therapy, stroke<3months, prior surgery target lesion,
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Rate of clinically driven target lesion revascularization (TLR) at 6 months</p><br>
- Secondary Outcome Measures
Name Time Method